<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004233</url>
  </required_header>
  <id_info>
    <org_study_id>20CH026</org_study_id>
    <secondary_id>2021-A00292-39</secondary_id>
    <nct_id>NCT05004233</nct_id>
  </id_info>
  <brief_title>Transmission Electron Microscopy Images for Platelet Ultrastructural Criteria Before and After the Onset of an Antiplatelet Agent</brief_title>
  <acronym>ELECTROSTROKE</acronym>
  <official_title>Transmission Electron Microscopy Images for Platelet Ultrastructural Criteria Before and After the Onset of an Antiplatelet Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the pilot study is to collect all the ultrastructural platelet characteristics by&#xD;
      transmission electron microscopy before and after the onset of an antiplatelet treatment in&#xD;
      patients hospitalized for an ischemic stroke ; and to assess recurrence of Ischemic Cerebral&#xD;
      Accident (ICA) at 6 months in patients hospitalized for Ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischaemic stroke is the leading cause of adult disability. Thus, a strategy based on an&#xD;
      efficient antiplatelet therapy has been developed to prevent platelet activation occurring in&#xD;
      the acute phase of non-cardioembolic ischemic stroke.&#xD;
&#xD;
      The biological monitoring of the antiplatelet therapy with available platelet function assays&#xD;
      do not provide a global integrative approach considering all the mechanisms involved in&#xD;
      platelet activation.&#xD;
&#xD;
      Platelet transmission electron microscopy recently validated for assessing distinct&#xD;
      ultrastructural abnormalities is a reliable morphological platelet structural analysis tool.&#xD;
&#xD;
      Ultrastructural criteria could be identified and be useful for the assessment of the degree&#xD;
      of platelet activation and thus the biological efficiency of antiplatelet agents. All the&#xD;
      activation transduction signals are integrated and all antiplatelet agents can be assessed.&#xD;
&#xD;
      The aim of the pilot study is to collect all the ultrastructural platelet characteristics by&#xD;
      transmission electron microscopy before and after the onset of an antiplatelet treatment in&#xD;
      patients hospitalized for an ischemic stroke.&#xD;
&#xD;
      Investigators expect to identify ultrastructural characteristics that will be correlated with&#xD;
      the platelet degree of activation to guide clinicians in decision-making regarding the&#xD;
      antiplatelet therapy strategy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2022</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphology of the platelet :</measure>
    <time_frame>Day 5</time_frame>
    <description>Platelet ultrastructural criteria will be obtained from transmission electron microscopy images of platelet ultrathin sections before and after (5 days) initiation of antiaggregant therapy in patients with noncardioembolic ICA&#xD;
the morphology of the platelet :&#xD;
discoid or round&#xD;
with the emission of filipodia, pseudopodia and lamellipodia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of granules in the platelet</measure>
    <time_frame>Day 5</time_frame>
    <description>Platelet ultrastructural criteria will be obtained from transmission electron microscopy images of platelet ultrathin sections before and after (5 days) initiation of antiaggregant therapy in patients with noncardioembolic ICA&#xD;
- the observation of granules :&#xD;
alpha granules&#xD;
dense granules</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of mitochondria, glycogen and dense tubular system in platelets</measure>
    <time_frame>Day 5</time_frame>
    <description>Platelet ultrastructural criteria will be obtained from transmission electron microscopy images of platelet ultrathin sections before and after (5 days) initiation of antiaggregant therapy in patients with noncardioembolic ICA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structure of open canalicular system in platelets</measure>
    <time_frame>Day 5</time_frame>
    <description>Platelet ultrastructural criteria will be obtained from transmission electron microscopy images of platelet ultrathin sections before and after (5 days) initiation of antiaggregant therapy in patients with noncardioembolic ICA&#xD;
- the open canalicular system&#xD;
dilated or not&#xD;
associated with degranulation or not</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with a microtubular ring on the equatorial section plane (peripheral or centralized) in platelets</measure>
    <time_frame>Day 5</time_frame>
    <description>Platelet ultrastructural criteria will be obtained from transmission electron microscopy images of platelet ultrathin sections before and after (5 days) initiation of antiaggregant therapy in patients with noncardioembolic ICA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of a composite endpoint</measure>
    <time_frame>Month 6</time_frame>
    <description>The incidence of a composite of cardiovascular events (radiologically documented recurrent ischemic stroke, transient ischemic attacks, coronary artery disease (acute coronary syndromes, myocardial infarction), obliterating arterial disease of the lower limb, death of cardiovascular origin)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Ischemic stroke patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients hospitalized for an ischemic stroke.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood collection before antiplatelet treatment</intervention_name>
    <description>Blood sample (17ml) will be collected in the neurovascular department to be processed for platelet ultrastructural analysis before the onset of an antiplatelet treatment</description>
    <arm_group_label>Ischemic stroke patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood collection after antiplatelet treatment</intervention_name>
    <description>A follow-up will be carried out 5 to 8 days after the initiation of the treatment.&#xD;
A blood test will be taken in the NeuroVascular Unit</description>
    <arm_group_label>Ischemic stroke patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Social security affiliation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  patients hospitalized for an non cardioembolic ischemic stroke requiring the onset of&#xD;
             an antiplatelet therapy according to the usual guidelines recommendations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Contraindications regarding antiplatelet agent(s) and/or at least one excipient according&#xD;
        to Summary of Product Characteristics (SPC).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PIERRE GARNIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU DE SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PIERRE GARNIER, MD</last_name>
    <phone>(0)477127805</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre.garnier@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nora MALLOUK, PhD</last_name>
    <phone>(0)4.77.42.14.34</phone>
    <phone_ext>+33</phone_ext>
    <email>nora.mallouk@univ-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de St-Etienne</name>
      <address>
        <city>Saint-Ã‰tienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Pierre GARNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali EPINAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic stroke</keyword>
  <keyword>Ultrastructural characterization</keyword>
  <keyword>Transmission electron microscopy</keyword>
  <keyword>platelet dysfunction</keyword>
  <keyword>Blood Coagulation Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

